Your browser doesn't support javascript.
The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics.
Schons, Maximilian; Pilgram, Lisa; Reese, Jens-Peter; Stecher, Melanie; Anton, Gabriele; Appel, Katharina S; Bahmer, Thomas; Bartschke, Alexander; Bellinghausen, Carla; Bernemann, Inga; Brechtel, Markus; Brinkmann, Folke; Brünn, Clara; Dhillon, Christine; Fiessler, Cornelia; Geisler, Ramsia; Hamelmann, Eckard; Hansch, Stefan; Hanses, Frank; Hanß, Sabine; Herold, Susanne; Heyder, Ralf; Hofmann, Anna-Lena; Hopff, Sina Marie; Horn, Anna; Jakob, Carolin; Jiru-Hillmann, Steffi; Keil, Thomas; Khodamoradi, Yascha; Kohls, Mirjam; Kraus, Monika; Krefting, Dagmar; Kunze, Sonja; Kurth, Florian; Lieb, Wolfgang; Lippert, Lena Johanna; Lorbeer, Roberto; Lorenz-Depiereux, Bettina; Maetzler, Corina; Miljukov, Olga; Nauck, Matthias; Pape, Daniel; Püntmann, Valentina; Reinke, Lennart; Römmele, Christoph; Rudolph, Stefanie; Sass, Julian; Schäfer, Christian; Schaller, Jens; Schattschneider, Mario.
  • Schons M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. nuep@mxschons.com.
  • Pilgram L; Department II of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt, Germany.
  • Reese JP; Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.
  • Stecher M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Anton G; German Center for Infection Research (DZIF), Partner-Site Cologne-Bonn, Cologne, Germany.
  • Appel KS; Institute of Epidemiology, Helmholtz Center Munich, Munich, Germany.
  • Bahmer T; German Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
  • Bartschke A; Department II of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt, Germany.
  • Bellinghausen C; Internal Medicine Department I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Bernemann I; Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany.
  • Brechtel M; Core Facility Digital Medicine and Interoperability, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Brinkmann F; Department of Respiratory Medicine and Allergology, Medical Clinic 1, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
  • Brünn C; Hannover Medical School, Hannover Unified Biobank, Hannover, Germany.
  • Dhillon C; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Fiessler C; Department of Paediatric Pneumology, Allergy and CF- Centre, University Children's Hospital, Ruhr- University Bochum, Bochum, Germany.
  • Geisler R; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Hamelmann E; COVID-19 Task Force, University Hospital Augsburg, Augsburg, Germany.
  • Hansch S; Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.
  • Hanses F; Department II of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt, Germany.
  • Hanß S; Department of Pediatrics, Children's Center Bethel, University Hospital East Westphalia, University Bielefeld, Bielefeld, Germany.
  • Herold S; Department for Infectious Diseases and Infection Control, University Hospital Regensburg, Regensburg, Germany.
  • Heyder R; Department for Infectious Diseases and Infection Control, University Hospital Regensburg, Regensburg, Germany.
  • Hofmann AL; Emergency Department, University Hospital Regensburg, Regensburg, Germany.
  • Hopff SM; University Medical Center Göttingen (UMG), Göttingen, Germany.
  • Horn A; German Center for Cardiovascular Diseases (DZHK), Berlin, Germany.
  • Jakob C; Department of Internal Medicine V, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Giessen, Germany.
  • Jiru-Hillmann S; Department of Internal Medicine, German Center for Lung Research (DZL), Universities of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University Giessen, Giessen, Germany.
  • Keil T; Institute for Lung Health (ILH), Giessen, Germany.
  • Khodamoradi Y; NUM Coordination Office, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Kohls M; Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.
  • Kraus M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Krefting D; Insitute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.
  • Kunze S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Kurth F; Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.
  • Lieb W; Insitute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.
  • Lippert LJ; Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Lorbeer R; State Institute of Health, Bavarian Health and Food Safety Authority, Bad Kissingen, Germany.
  • Lorenz-Depiereux B; Department of Infectious Diseases, Medical Clinic 2, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
  • Maetzler C; Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.
  • Miljukov O; Institute of Epidemiology, Helmholtz Center Munich, Munich, Germany.
  • Nauck M; German Center for Cardiovascular Research (DZHK), Partner Site Munich, Munich, Germany.
  • Pape D; University Medical Center Göttingen (UMG), Göttingen, Germany.
  • Püntmann V; German Center for Cardiovascular Diseases (DZHK), Berlin, Germany.
  • Reinke L; Institute of Epidemiology, Helmholtz Center Munich, Munich, Germany.
  • Römmele C; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Rudolph S; Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Medicine I, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
  • Sass J; Institute of Epidemiology, Kiel University, Kiel, Germany.
  • Schäfer C; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Schaller J; Department of Radiology, University Hospital, LMU, Munich, Germany.
  • Schattschneider M; Medical Heart Center of Charité and German Heart Institute Berlin, Institute of Computer-Assisted Cardiovascular Medicine, Berlin, Germany.
Eur J Epidemiol ; 37(8): 849-870, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1966157
ABSTRACT
The German government initiated the Network University Medicine (NUM) in early 2020 to improve national research activities on the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. To this end, 36 German Academic Medical Centers started to collaborate on 13 projects, with the largest being the National Pandemic Cohort Network (NAPKON). The NAPKON's goal is creating the most comprehensive Coronavirus Disease 2019 (COVID-19) cohort in Germany. Within NAPKON, adult and pediatric patients are observed in three complementary cohort platforms (Cross-Sectoral, High-Resolution and Population-Based) from the initial infection until up to three years of follow-up. Study procedures comprise comprehensive clinical and imaging diagnostics, quality-of-life assessment, patient-reported outcomes and biosampling. The three cohort platforms build on four infrastructure core units (Interaction, Biosampling, Epidemiology, and Integration) and collaborations with NUM projects. Key components of the data capture, regulatory, and data privacy are based on the German Centre for Cardiovascular Research. By April 01, 2022, 34 university and 40 non-university hospitals have enrolled 5298 patients with local data quality reviews performed on 4727 (89%). 47% were female, the median age was 52 (IQR 36-62-) and 50 pediatric cases were included. 44% of patients were hospitalized, 15% admitted to an intensive care unit, and 12% of patients deceased while enrolled. 8845 visits with biosampling in 4349 patients were conducted by April 03, 2022. In this overview article, we summarize NAPKON's design, relevant milestones including first study population characteristics, and outline the potential of NAPKON for German and international research activities.Trial registration https//clinicaltrials.gov/ct2/show/NCT04768998 . https//clinicaltrials.gov/ct2/show/NCT04747366 . https//clinicaltrials.gov/ct2/show/NCT04679584.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Child / Female / Humans / Male / Middle aged Language: English Journal: Eur J Epidemiol Journal subject: Epidemiology Year: 2022 Document Type: Article Affiliation country: S10654-022-00896-z

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Child / Female / Humans / Male / Middle aged Language: English Journal: Eur J Epidemiol Journal subject: Epidemiology Year: 2022 Document Type: Article Affiliation country: S10654-022-00896-z